Veracyte Inc. (VCYT)
| Bid | 29.81 |
| Market Cap | 2.44B |
| Revenue (ttm) | 447.69M |
| Net Income (ttm) | 24.24M |
| EPS (ttm) | 0.31 |
| PE Ratio (ttm) | 100.97 |
| Forward PE | 49.5 |
| Analyst | Buy |
| Ask | 35.12 |
| Volume | 467,914 |
| Avg. Volume (20D) | 1,068,771.6 |
| Open | 30.95 |
| Previous Close | 31.23 |
| Day's Range | 30.32 - 31.31 |
| 52-Week Range | 18.61 - 47.32 |
| Beta | 1.80 |
About VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ...
Analyst Forecast
According to 7 analyst ratings, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 40.58% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Veracyte Announces Fourth Quarter and Full Year 2024 Financial ResultsSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I'm incredibly proud of wha...
